Funded through launch: secured up to $26 million of capital without an equity offering
The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk
The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee
On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027
Login to comment